Recent developments include FDA regulatory interactions, clinical data releases, insider buying, capital raises, and corporate communications highlighting clinical symposium participation.

• enVVeno Medical received a non-approvable letter from the FDA for the VenoValve PMA application in August 2025, with an unsuccessful appeal thereafter [N1][S1].
• The company revealed promising 2-year clinical trial data from the VenoValve pivotal study in June 2025 [N2].
• enVVeno completed and submitted the VenoValve PMA application to the FDA in November 2024 [N7][N8].
• The company launched a recap website highlighting participation in the VEITH Symposium in November 2024 [N6].
• Insider buying was reported in early January 2025, including a director purchasing 81,433 shares [N4][N5].
• enVVeno reported Q3 2024 EPS of -$0.35 compared to -$0.45 the prior year and expects capital to fund operations through several milestones [N1].
• The company is advancing the enVVe System development and plans to begin pivotal trials following FDA discussions [S1].

The company has demonstrated promising clinical data from the VenoValve pivotal study and is advancing a next-generation, less invasive enVVe System designed to address prior FDA concerns and broaden physician adoption. The enVVe System's minimally invasive catheter-based approach could appeal to a wider range of specialists, potentially expanding market reach. The company's strong patent portfolio and manufacturing capabilities support product development and potential commercialization. Insider buying activity and capital raises indicate confidence in the company's progress. If regulatory approvals are obtained, enVVeno could address a large unmet need in severe CVI treatment.

The VenoValve received a non-approvable letter from the FDA, and the appeal was unsuccessful, highlighting regulatory risk. The enVVe System remains in pre-clinical stages with pivotal trials pending FDA approval, introducing clinical and regulatory uncertainties. The company has reported net losses and negative earnings per share, reflecting ongoing development costs and lack of revenue. The medical device market for venous valves is unproven with no currently approved products, posing commercialization and adoption risks. The company may face challenges in building sales and marketing infrastructure and scaling manufacturing. Dependence on FDA approvals and potential delays or unfavorable outcomes present significant risks.

enVVeno's moat is based on its proprietary tissue processing and manufacturing methodologies for biologic implantable devices, extensive patent portfolio including 42 granted patents worldwide, and its ISO-certified manufacturing facility tailored for Class III tissue-based medical devices. The company benefits from clinical data and experience gained from the VenoValve program, which informs the development of the next-generation enVVe System. The lack of currently approved replacement venous valves and the significant unmet medical need in severe CVI patients provide a potential competitive advantage if regulatory approvals are obtained. The company's experienced management and advisory teams with prior FDA approval experience also contribute to its competitive positioning.

• Regulatory Approval Risk: The company’s products require FDA pre-market approval, which is a demanding process with no guarantee of success. The VenoValve received a non-approvable letter, and the enVVe System is still in pre-clinical stages requiring IDE and PMA approvals.
• Clinical Trial Risk: The enVVe System pivotal trial is planned but not yet initiated. Clinical trial outcomes may affect regulatory approval and commercial viability.
• Financial Risk: The company reported net losses and negative EPS, indicating ongoing expenses without revenue. Adequate capital is necessary to fund development and commercialization.
• Market Adoption Risk: There are no currently approved replacement venous valves, and the market is unproven. Adoption by physicians and payers is uncertain.
• Manufacturing and Operational Risk: The company relies on a single manufacturing facility, which could be disrupted by disasters or operational issues, potentially impacting supply and reputation.

• enVVeno Medical Corp is a medical device company focused on developing bioprosthetic tissue-based solutions for venous disease treatment, specifically targeting chronic venous insufficiency (CVI), a severe subset of chronic venous disease (CVD).
• The company developed the VenoValve, a first-in-class surgical replacement venous valve, which received a non-approvable letter from the FDA in August 2025 and an unsuccessful appeal thereafter.
• enVVeno is now focused on the enVVe System, a next-generation, non-surgical, transcatheter-based replacement venous valve designed to treat severe CVI with a minimally invasive catheter approach.
• The enVVe System includes the enVVe Valve, Delivery System, Nose Cone, Delivery System Accessories, and Crimping System, and has completed pre-clinical testing with ongoing FDA discussions regarding a pivotal trial anticipated to begin in 2026.
• The company operates a 14,507 sq. ft. ISO 13485-2016 certified manufacturing facility in Irvine, California, for design, development, and manufacturing of tissue-based implantable medical devices.
• There are currently no FDA-approved surgical or non-surgical replacement venous valves, and no effective treatments for deep venous CVI caused by incompetent valves.
• The VenoValve pivotal clinical study (SAVVE) enrolled 75 patients and data has been presented globally, showing promising efficacy for a difficult-to-treat patient population.
• The company has filed numerous patent applications worldwide for the VenoValve and enVVe System, holding 42 patents granted globally including 9 from the USPTO.
• enVVeno had 33 full-time employees as of March 24, 2026, with no collective bargaining agreements or work stoppages.
• The company submitted the VenoValve PMA application to the FDA in November 2024, completed the application in November 2024, but received a non-approvable letter in August 2025.
• The enVVe System requires FDA pre-market approval (PMA) and investigational device exemption (IDE) approval before human clinical trials in the U.S.
• The company has reported Q3 2024 EPS of -$0.35 compared to -$0.45 the prior year, and expects capital to fund operations through several milestones.
• As of June 30, 2026, enVVeno had cash and equivalents of $2.84 million, short-term investments of $18.65 million, current assets of $22.08 million, and current liabilities of $1.89 million, resulting in a current ratio of 11.7 and cash ratio of 11.39.
• The company reported a net loss of $3.6 million and basic and diluted EPS of -$5.37 for the quarter ended June 30, 2026.
• Insider buying activity was reported in early 2025, including a director purchasing 81,433 shares.
• The company launched a recap website highlighting participation in the VEITH Symposium in November 2024.
• The FDA review outcome for the VenoValve was unfavorable, impacting shares in August 2025.
• The company is advancing the enVVe System development and plans to begin pivotal trials following FDA discussions.
• The company completed the VenoValve PMA application and submitted it to the FDA in late 2024.
• The company is focused on the U.S. market for the enVVe System and has foregone approval efforts for the VenoValve outside the U.S.